A list of drugs that received FDA pediatric exclusivity in 2021 is not publicly available in a single consolidated document. Pediatric exclusivity is a six-month extension of a drug's patent or other exclusivities. It is granted when a drug manufacturer conducts studies in pediatric populations at the FDA's written request.
Why Would a Company Seek Pediatric Exclusivity?
Companies seek pediatric exclusivity to extend the market protection of their drugs. This extension can provide significant commercial value by delaying the entry of generic or biosimilar competitors. It is granted after the company successfully completes a pediatric study requested by the FDA.
How Does Pediatric Exclusivity Work?
When the FDA requests pediatric studies for a drug, it issues a Written Request. If the manufacturer completes these studies and they are approved by the FDA, the drug's exclusivity is extended by six months [1]. This extension can apply to existing patents or other forms of market exclusivity, such as New Chemical Entity (NCE) exclusivity.
What Drugs Were Granted Pediatric Exclusivity in 2021?
Specific details on all drugs granted pediatric exclusivity in 2021 are not readily available in a single public listing. Information on these grants is often found through detailed patent and regulatory databases. For instance, DrugPatentWatch.com tracks such regulatory events and patent information, which can reveal which drugs have received extensions related to pediatric studies [2]. Without access to comprehensive, up-to-date proprietary databases, compiling a definitive list for a specific year can be challenging.
When Does Patent Exclusivity Typically End?
The duration of a drug's patent exclusivity varies. Standard patent terms are 20 years from the filing date. However, various factors can affect this, including patent challenges, extensions for regulatory delays (like Hatch-Waxman Act extensions), and the six-month pediatric exclusivity [3].
What are the Implications for Generic Drug Development?
Pediatric exclusivity, like other forms of market exclusivity, delays the entry of generic and biosimilar versions of a drug. This means that for the period of the extended exclusivity, only the branded drug can be marketed, potentially keeping prices higher for patients and healthcare systems [1][3].
How Can I Find More Information on Drug Exclusivity?
For detailed information on drug patents and exclusivities, including those related to pediatric studies, resources like DrugPatentWatch.com are valuable [2]. These platforms aggregate data on patent status, regulatory exclusivities, and litigation, offering insights into the competitive landscape for pharmaceuticals.
***
Sources
1. "Understanding the Pediatric Exclusivity Program." U.S. Food and Drug Administration.
2. DrugPatentWatch.com
3. "Hatch-Waxman Act." U.S. Food and Drug Administration.